209 related articles for article (PubMed ID: 2973169)
1. Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
Schulze H; Kaldenhoff H; Senge T
Urol Int; 1988; 43(4):193-7. PubMed ID: 2973169
[TBL] [Abstract][Full Text] [Related]
2. Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
Bouffioux C
Eur Urol; 1988; 15(3-4):187-92. PubMed ID: 2975222
[TBL] [Abstract][Full Text] [Related]
3. Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.
Carvalho AP; de Moura JL; Denis L; Newling D; Smith P; Bono A; Sylvester R; De Pauw M; Ongena P
Prog Clin Biol Res; 1989; 303():129-43. PubMed ID: 2528736
[No Abstract] [Full Text] [Related]
4. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
Lunglmayr G
Prog Clin Biol Res; 1989; 303():145-51. PubMed ID: 2528737
[TBL] [Abstract][Full Text] [Related]
5. Maximal androgen blockade in prostatic cancer.
Denis L
Scand J Urol Nephrol Suppl; 1991; 138():137-44. PubMed ID: 1838427
[No Abstract] [Full Text] [Related]
6. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
Peeling WB
Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
[TBL] [Abstract][Full Text] [Related]
7. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
Iversen P
Eur Urol; 1990; 18 Suppl 3():41-4. PubMed ID: 2151275
[TBL] [Abstract][Full Text] [Related]
8. Complete androgen blockade: data from an EORTC 30853 trial.
Denis L; Keuppens F; Robinson M; Mahler C; Smith P; Pinto de Carvalho AP; Newling D; Bono A; Sylvester R; De Pauw M
Semin Urol; 1990 Aug; 8(3):166-74. PubMed ID: 2144656
[No Abstract] [Full Text] [Related]
9. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
10. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
Iversen P; Suciu S; Sylvester R; Christensen I; Denis L
Cancer; 1990 Sep; 66(5 Suppl):1067-73. PubMed ID: 2144208
[TBL] [Abstract][Full Text] [Related]
11. LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
Denis L
Horm Res; 1989; 32 Suppl 1():66-7; discussion 68. PubMed ID: 2533158
[TBL] [Abstract][Full Text] [Related]
12. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
Ayub M; Levell MJ
Clin Endocrinol (Oxf); 1990 Mar; 32(3):329-39. PubMed ID: 2140542
[TBL] [Abstract][Full Text] [Related]
13. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Lunglmayr G
Eur Urol; 1990; 18 Suppl 3():28-9. PubMed ID: 2151273
[No Abstract] [Full Text] [Related]
14. Advantages of total androgen blockade in the treatment of advanced prostate cancer.
Geller J; Albert J; Vik A
Semin Oncol; 1988 Apr; 15(2 Suppl 1):53-61. PubMed ID: 3285484
[TBL] [Abstract][Full Text] [Related]
15. LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy--a phase II study.
Iversen P; Rose C; Stage JG; Iversen HG; Hansen RI; Hvidt V; Mogensen P; Pedersen T; Hansen JB
Scand J Urol Nephrol; 1989; 23(3):177-83. PubMed ID: 2529629
[TBL] [Abstract][Full Text] [Related]
16. Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
Tyrrell CJ; Altwein JE; Klippel F; Jurincic-Winkler C; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
Eur Urol; 2000 Feb; 37(2):205-11. PubMed ID: 10705200
[TBL] [Abstract][Full Text] [Related]
17. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
Denis L; Robinson M; Mahler C; Smith P; Keuppens F; De Moura JL; Bono A; Newling D; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):951-9. PubMed ID: 2149508
[TBL] [Abstract][Full Text] [Related]
18. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
Fourcade RO; Cariou G; Coloby P; Colombel P; Coulange C; Grise P; Mangin P; Soret JY; Poterre M
Eur Urol; 1990; 18 Suppl 3():45-7. PubMed ID: 2151276
[TBL] [Abstract][Full Text] [Related]
19. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Schulze H; Senge T
J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
[TBL] [Abstract][Full Text] [Related]
20. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate.
Peeling WB
Prog Clin Biol Res; 1989; 303():41-5. PubMed ID: 2528738
[No Abstract] [Full Text] [Related]
[Next] [New Search]
